• News & Media
  • Contact
  • Home
  • About Us
    • Our Commitment
    • The Story Behind Our Name
    • Leadership
    • Board of Directors
    • Grants & Funding
    • Investigator Sponsored Studies
  • Our Approach
    • Precision Medicines
    • Overcoming Resistance
    • Novel Biomarkers
  • Pipeline
    • Ziftomenib
    • Tipifarnib
    • KO-2806
    • Posters and Presentations
    • Scientific Manuscripts
    • Access To Investigational Drugs Outside a Clinical Study
  • Clinical Trials
    • Overview of Clinical Trials
    • Ziftomenib Clinical Trials
    • KOMET-001 – AML
    • KOMET-007 – AML
    • KOMET-008 – AML
    • Tipifarnib Clinical Trials
    • KURRENT-HN – HNSCC
    • KO-2806 Clinical Trials
    • FIT-001 – Solid Tumors
  • Patients & Caregivers
    • Acute Leukemias
    • Head & Neck Cancer
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • FAQs
    • Contact
  • Careers
    • Values
    • Life At Kura
    • Benefits
    • Open Positions
  • News & Media
  • Contact
  • Menu Menu

The promise of precision oncology

brought to life for patients

Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress

VIEW MORE IN THE PRESS RELEASE

Our mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives.

Our novel therapies are designed to target cancer cells selectively, increasing clinical benefit while moving the field forward in areas with the highest unmet needs. Just as vital to our mission, we’re investigating our novel therapies in combination with standards of care, forging new paths to give patients a better chance for long-term durable remissions.

We Are Kura

elder couple holding hands at the beach

Our Commitment

We discover and develop novel cancer therapeutics that seek to improve patient outcomes and enable more patients to benefit.

About Us

Our Course

Through our evolving understanding of the molecular processes that drive cancer, we’re pioneering new approaches to treat devastating diseases, including head and neck cancer, lung cancer and acute leukemias.

Pipeline

Our Culture

We are courageous, science-driven innovators who work as one to create new possibilities for patients.

Careers

Our Heroes

Patients and caregivers: You are the “why” behind the work we do every day. Access resources and learn more about our approach.

Patients & Caregivers
father and son embracing

Kura In The News

gear bridge

What pharma can teach biotech about the life cycle management of a drug

May 18, 2023/in Currents
Read more
https://kuraoncology.com/wp-content/uploads/pharma_voice_gears.jpeg 450 800 eallison /wp-content/uploads/kura-logo-registered-blue.svg eallison2023-05-18 08:00:542023-05-23 13:57:17What pharma can teach biotech about the life cycle management of a drug
chart

Navigating dose optimization requirements as a small biotech

February 1, 2023/in Currents
Read more
https://kuraoncology.com/wp-content/uploads/BioCentury_0201_DB_DoseOptim.png 646 1246 David Anderson /wp-content/uploads/kura-logo-registered-blue.svg David Anderson2023-02-01 08:00:002023-02-07 14:03:52Navigating dose optimization requirements as a small biotech
dna and cells

Liquid Biopsies Guide the Development of Cancer Drugs

September 6, 2022/in Currents

Liquid Biopsies Guide the Development of Cancer Drugs

Read more
https://kuraoncology.com/wp-content/uploads/LiquidBiopsies_GettyImages-1325872227-1068x712-1.jpg 712 1068 David Anderson /wp-content/uploads/kura-logo-registered-blue.svg David Anderson2022-09-06 14:25:062023-01-05 12:40:46Liquid Biopsies Guide the Development of Cancer Drugs
troy wilson in a lab

Fierce Biotech: FDA’s renewed focus on oncology dosing spooks investors, but companies say they’re ready

June 28, 2021/in Currents
Read more
https://kuraoncology.com/wp-content/uploads/troy_wilson_lab.png 478 850 David Anderson /wp-content/uploads/kura-logo-registered-blue.svg David Anderson2021-06-28 12:00:192022-12-01 16:51:22Fierce Biotech: FDA’s renewed focus on oncology dosing spooks investors, but companies say they’re ready
paper and charts

ESMO: Tipifarnib demonstrates encouraging efficacy in patients with recurrent and/or metastatic hnscc with hras mutations

April 21, 2021/in Currents
Read more
https://kuraoncology.com/wp-content/uploads/AdobeStock_207889815-scaled.jpg 1709 2560 David Anderson /wp-content/uploads/kura-logo-registered-blue.svg David Anderson2021-04-21 12:00:292022-11-16 13:32:04ESMO: Tipifarnib demonstrates encouraging efficacy in patients with recurrent and/or metastatic hnscc with hras mutations
MRI scanner analysis

Journal of Clinical Oncology: Is This the Dawn of Precision Oncology in Head and Neck Cancer?

April 20, 2021/in Currents
Read more
https://kuraoncology.com/wp-content/uploads/Kura_Dawn-of-Medicine-Article-img-scaled.jpeg 1709 2560 David Anderson /wp-content/uploads/kura-logo-registered-blue.svg David Anderson2021-04-20 06:00:022022-11-16 13:25:55Journal of Clinical Oncology: Is This the Dawn of Precision Oncology in Head and Neck Cancer?
  • About Us
  • Our Commitment
  • The Story Behind Our Name
  • Leadership
  • Board of Directors
  • Grants & Funding
  • Investigator Sponsored Studies
  • Our Approach
  • Precision Medicines
  • Overcoming Resistance
  • Novel Biomarkers
  • Pipeline
  • Ziftomenib
  • Tipifarnib
  • KO-2806
  • Posters and Presentations
  • Scientific Manuscripts
  • Access to Investigational Drugs Outside a Clinical Study
  • Clinical Trials
  • Overview of Clinical Trials
  • Ziftomenib Clinical Trials
  • KOMET-001 – AML
  • KOMET-007 – AML
  • KOMET-008 – AML
  • Tipifarnib Clinical Trials
  • KURRENT-HN – HNSCC
  • KO-2806 Clinical Trials
  • FIT-001 – Solid Tumors
  • Patients & Caregivers
  • Acute Leukemias
  • Head & Neck Cancer
  • Investors
  • Overview
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financial Information
  • Analyst Coverage
  • FAQs
  • Contact
  • Careers
  • Values
  • Life at Kura
  • Benefits
  • Open Positions
  • News & Media
  • Press Releases
  • News & Perspectives
  • Expert Perspectives
  • Media Resources
  • Contact

Kura Oncology, Inc.
12730 High Bluff Drive, Suite 400
San Diego, CA 92130
(858) 500-8800

Kura Oncology, Inc.
2 Seaport Lane, Suite 8A
Boston, MA 02210
(617) 588-3755

Kura Oncology, Inc.
5510 Morehouse Drive, Suite 110
San Diego, California 92121

© 2025 Kura Oncology, Inc. All Rights Reserved | Terms of Use | Privacy Policy

Scroll to top Scroll to top Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlySettings

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Accept settingsHide notification only